In a world where clinical trials can make or break the success of a new medication, there's one critical factor that can't be overlooked: medication adherence. That's where our blog comes in. We're here to provide you with the latest industry news, practical tips, and expert advice on everything related to medication adherence in trials.
The economic model that has underpinned the development of drug products for decades is currently under siege.
Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside. In recent years, the pharmaceutical industry has borne witness to the meteoric rise of glucagon-like peptide-1 receptor agonist GLP-1 therapies.
Having fast become established as a potentially life-changing treatment for Type 2 diabetes and obesity, emerging evidence of the cardio and. Let us first recognise the enormity of the challenges we are facing, on a global scale, when it comes to cancer.
It is estimated that there were Medication adherence is a vital component in managing chronic diseases effectively. This lack of adherence results in poor health outcomes and increased burdens on healthcare. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. In a clinical trial, every piece of data contributes to the overall story being told. No matter how small or seemingly insignificant, all the information that emerges over the course of the process adds rich detail to the narrative.
